Abbott Laboratories (ABT) operating KPIs
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — Worldwide Revenue ($M) ($M)
New Diagnostics subsegment formed upon closing the $21B ($23B EV) acquisition of Exact Sciences Corporation in Q1 2026.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — Worldwide Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 968 | – | SEC Filing (0001628280-26-066601) ↗ |
| Q2 2026 | Jun 30, 2026 | 919 | – | SEC Filing (0001628280-26-048377) ↗ |
| Q1 2026 | Mar 31, 2026 | 96 | – | SEC Filing (0001628280-26-025365) ↗ |
| Q2 2025 | Jun 30, 2025 | 0 | – | SEC Filing (0001628280-26-050134) ↗ |
| Q1 2025 | Mar 31, 2025 | 0 | – | SEC Filing (0001628280-26-028357) ↗ |
Breakdown
What makes up cancer diagnostics division (exact sciences — cologuard, oncotype dx & simplescreen crc) — worldwide revenue ($m)
- Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — Organic / Comparable Sales Growth (%)13.8% · Q3 2026
- Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — U.S. Revenue ($M)938 · Q3 2026
- Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — International Revenue ($M)30 · Q3 2026
Cite this data
StockData. (2026). Abbott Laboratories Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — Worldwide Revenue ($M) ($M), quarterly Q1 2025–Q3 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-cancer-rev-ww
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.